1 / 3

ASCOT-LLA Extension Study

ASCOT-LLA Extension Study. Objective 11-year mortality follow-up of the lipid-lowering arm of ASCOT in the UK Background

haruko
Download Presentation

ASCOT-LLA Extension Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASCOT-LLA Extension Study Objective • 11-year mortality follow-up of the lipid-lowering arm of ASCOT in the UK Background • ASCOT-LLA: 10,305 subjects with hypertension and a total cholesterol level of ≤6.5 mmol/L (250 mg/dL) were randomly assigned to atorvastatin or placebo in the ASCOT-LLA Study • After a median follow-up of 3.3 years, ASCOT-LLA was terminated due to overwhelming benefit with atorvastatin • Investigators continued to collect mortality data in the UK cohort (n=4605) for a total median follow-up of 11 years from initial randomization* *Most patients who were initially randomized to atorvastatin therapy continued to take atorvastatin (63%), while a minority (4%) took another statin; most patients in the placebo group switched to atorvastatin (56%), and a small number initiated therapy with another statin (7%).

  2. ASCOT-LLA Extension Study Results • In the ASCOT-LLA extension group, the risk of all-cause mortality was 14% lower for those initially assigned to atorvastatin compared with placebo • Patients initially randomized to atorvastatin had a lower long-term risk of death due to infections and respiratory illness • There was no difference in the risk of death due to CV causes Conclusions • These observations may suggest a legacy benefit in terms of reduced mortality with atorvastatin

  3. ASCOT-LLA Extension Study Adjusted Effect of Atorvastatin on Mortality and Causes of Death

More Related